Influence of alendronate therapy on the results of densitometric examination after implantation of total hip endoprosthesis

Shabani, Ilir; Gavrilovski, Antonio; Velkovski, Vilijam; Atanasov, Nenad; Memeti, Shaban; Belchishta, Anila

doi:10.3889/aph.2021.5994

Influence of alendronate therapy on the results of densitometric examination after implantation of total hip endoprosthesis

Journal

Archives of Public Health

Date Issued

2021-06-20

Author(s)

Shabani, Ilir

Velkovski, Vilijam

Belchishta, Anila

DOI

10.3889/aph.2021.5994

Abstract

The development of aloarthroplasty of the hip is continuously rising. After implantation of a total cement-free hip endoprosthesis, often there is a periprosthetic femoral bone loss. Alendronate has been shown to be a potent inhibitor of bone resorption activity; it inhibits osteoclastic bone resorption, increases bone mass, and plays a significant role in post-implantation stabilization of the femur. The aim of this study was to determine the effect of alendronate on osteointegration of hip endoprosthesis.Material and methods: The study analyzed 10 patients operated on with implantation of a total cement-free hip endoprosthesis (THP). The included patients were examined by a radiographic method at 6 and 12 months and DXA method at 6 and 12 months. Results: The study showed differences in the values of bone mineral density and bone mineral content in the interval between 6 and 12 months in patients undergoing THP, and hence we can conclude that alendronate therapy after THP implantation reduced periprosthetic loss of bone mass and implant stiffening. Alendronate is a proven inhibitor of periprosthetic bone loss that occurs after prirmary impantation of a total cement-free hip endoprosthesis.